+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2018

  • ID: 4622998
  • Drug Pipelines
  • September 2018
  • Region: Global
  • 73 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Coherus BioSciences Inc
  • Formycon AG
  • Lupin Ltd
  • Oxurion NV
  • MORE
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2018

Summary:

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2018'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 13 molecules.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor - Pipeline Review, H2 2018' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 5 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Macular Edema, Retinal Vein Occlusion, Medulloblastoma, Metastatic Colorectal Cancer, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Coherus BioSciences Inc
  • Formycon AG
  • Lupin Ltd
  • Oxurion NV
  • MORE
Introduction

Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Momenta Pharmaceuticals Inc

Oxurion NV

Regeneron Pharmaceuticals Inc

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones

Featured News & Press Releases

Aug 17, 2018: FDA approves EYLEA (aflibercept) injection sBLA in wet age-related macular degeneration

Aug 13, 2018: Regeneron Provides Regulatory Update on EYLEA (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Aug 01, 2018: Bayer receives approval of new treatment regimen for Eylea in the EU

Jul 19, 2018: ThromboGenics Reports Day 150 Top line Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema

Jun 13, 2018: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

May 23, 2018: ThromboGenics to present a preclinical overview of its most advanced diabetic eye disease clinical candidate, THR-317, at EASDec 2018

May 11, 2018: Bayer receives approval for Eylea in China

Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME

Apr 04, 2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-

Mar 20, 2018: Aflibercept shows promising data for non proliferative DR

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 28, 2018: Regeneron Letter to Healthcare Professionals Re: EYLEA (aflibercept) Injection

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Alteogen Inc, H2 2018

Pipeline by Benitec Biopharma Ltd, H2 2018

Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Pipeline by Coherus BioSciences Inc, H2 2018

Pipeline by Formycon AG, H2 2018

Pipeline by Lupin Ltd, H2 2018

Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Pipeline by Oxurion NV, H2 2018

Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Coherus BioSciences Inc
  • Formycon AG
  • Lupin Ltd
  • Momenta Pharmaceuticals Inc
  • Oxurion NV
  • Regeneron Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll